Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarro.

Scholar Rock to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 28,100 shares of common stock and inducemen.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2023. “We are executing across our business and leveraging Scholar Rock's differentiated platform, which selectively targets latent forms of growth factors, such as myostatin and TGFβ1, to.

Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab. Apitegromab is an investigational antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myo.

Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock's Board of Directors as an independent director. Mr.

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022. “2023 is off to a great start as we continue to build upon our momentum from last year.

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective inhibitor of the activation of myostatin for spinal muscular atrophy (SMA).

Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.

Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy. At Scholar Rock, she will build and lead all commercial functions, including sales, marketing, market access, and commercial operations. Her first priority will be preparing the company for the potential commercial launch of apitegromab, the company's Phase 3 investigational candidate for spinal muscular atrophy (SMA).

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET).

Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022. The award is subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Plan (the “Plan”) and form of stock option agreement thereunder.

Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2022.

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz, M.D.

Scholar Rock to Participate in Upcoming Investor Conferences

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Shares are down 70% thus far in 2022. TOPAZ data update for apitegromab in SMA was encouraging (as reflected in increases in HFMSE and RULM scores).

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present Data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors, at SITC Annual Meeting.

Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at WMS Congress and International Scientific Congress on Spinal Muscular Atrophy.

Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2022. “We are pleased to have reported important progress with our two clinical programs during the second quarter. Enrollment continues to advance in our pivotal Phase 3 SAPPHIRE trial for

Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock's Board of Directors as an independent director.

Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the “Muscle Beach” panel for the 2022 Wedbush PacGrow Healthcare Conference, being held virtually on August 9, 2022, at 2:20 pm ET. A live webcast of the panel may be accessed by visiting the Investors & Media section of the

News for Scholar Rock Holding Corp Stock (SRRK)